Should Renvela (sevelamer carbonate) be continued in a patient who is NPO (nothing by mouth), and how should phosphate be managed until oral intake resumes?

Renvela (Sevelamer) Should Be Discontinued in NPO Patients

Discontinue Renvela immediately when a patient is made NPO, as phosphate binders require food in the gastrointestinal tract to bind dietary phosphorus and have no therapeutic effect without oral intake. 1

Mechanism and Rationale for Discontinuation

• Sevelamer works exclusively by binding dietary phosphate within the gastrointestinal tract to prevent absorption and enhance fecal excretion 2
• The medication must be administered 10-15 minutes before or during meals because phosphate binders function by binding dietary phosphorus in the GI tract 1, 3
• Taking phosphate binders between meals or without food results in markedly reduced efficacy and provides no therapeutic benefit 4
• Without oral intake, there is no dietary phosphorus to bind, rendering the medication completely ineffective 1

Phosphate Management During NPO Status

Monitor serum phosphorus levels every 2-4 weeks during the NPO period, as phosphorus will naturally decline without dietary intake. 3, 4

Expected Phosphorus Changes

• Serum phosphorus typically decreases when dietary intake is eliminated, as the primary source of phosphorus is removed 5
• In CKD patients, target phosphorus levels are 3.5-5.5 mg/dL for Stage 5 and 2.7-4.6 mg/dL for Stages 3-4 1, 3

When to Resume Sevelamer

• Restart sevelamer only when oral or enteral nutrition resumes and the patient is receiving meals containing phosphorus 1, 3
• If the patient transitions to enteral feeding via feeding tube, sevelamer tablets may be crushed and administered through the tube, though this requires clear preparation protocols 6
• Resume at the previous effective dose when full nutritional intake is restored 3

Common Pitfalls to Avoid

• Do not continue sevelamer "just in case" – this wastes medication and provides no benefit without dietary phosphorus 1
• Do not assume phosphorus will rise during NPO status – it typically falls due to absence of dietary intake 5
• Avoid switching to calcium-based binders during NPO periods, as they also require food to bind phosphorus and would be equally ineffective 4
• Remember that sevelamer carbonate increases serum bicarbonate, so discontinuation may affect acid-base status in patients with metabolic acidosis 3, 2

Monitoring During NPO Period

• Check serum phosphorus, calcium, and PTH levels regularly to assess mineral metabolism 3
• Monitor for hypophosphatemia if NPO status is prolonged, particularly in patients with baseline normal or low phosphorus 5
• Maintain calcium-phosphorus product <55 mg²/dL² to reduce calcification risk 3